Catalyst Pharmaceuticals (CPRX) Competitors

Catalyst Pharmaceuticals (NASDAQ:CPRX) and Qiagen (NYSE:QGEN) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, community ranking, dividends, risk, earnings, media sentiment and valuation.

Which has more risk and volatility, CPRX or QGEN?

Catalyst Pharmaceuticals has a beta of 0.75, suggesting that its stock price is 25% less volatile than the S&P 500. Comparatively, Qiagen has a beta of 0.35, suggesting that its stock price is 65% less volatile than the S&P 500.

Is CPRX or QGEN more profitable?

Catalyst Pharmaceuticals has a net margin of 31.01% compared to Qiagen's net margin of 4.73%. Catalyst Pharmaceuticals' return on equity of 40.79% beat Qiagen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Catalyst Pharmaceuticals	31.01%	40.79%	34.87%
Qiagen	4.73%	13.43%	8.10%

Does the media favor CPRX or QGEN?

In the previous week, Catalyst Pharmaceuticals had 1 more articles in the media than Qiagen. MarketBeat recorded 6 mentions for Catalyst Pharmaceuticals and 5 mentions for Qiagen. Catalyst Pharmaceuticals' average media sentiment score of 1.13 beat Qiagen's score of 0.47 indicating that Catalyst Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Catalyst Pharmaceuticals	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Qiagen	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Which has stronger valuation & earnings, CPRX or QGEN?

Qiagen has higher revenue and earnings than Catalyst Pharmaceuticals. Catalyst Pharmaceuticals is trading at a lower price-to-earnings ratio than Qiagen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Catalyst Pharmaceuticals	$460.48M	5.51	$71.41M	$1.18	18.03
Qiagen	$1.97B	5.18	$341.30M	$0.39	114.54

Does the MarketBeat Community believe in CPRX or QGEN?

Catalyst Pharmaceuticals received 244 more outperform votes than Qiagen when rated by MarketBeat users. Likewise, 74.70% of users gave Catalyst Pharmaceuticals an outperform vote while only 60.88% of users gave Qiagen an outperform vote.

Company	Underperform	Outperform
Catalyst Pharmaceuticals	Outperform Votes 493 74.70%	Underperform Votes 167 25.30%
Qiagen	Outperform Votes 249 60.88%	Underperform Votes 160 39.12%

Do institutionals & insiders have more ownership in CPRX or QGEN?

79.2% of Catalyst Pharmaceuticals shares are held by institutional investors. Comparatively, 70.0% of Qiagen shares are held by institutional investors. 11.0% of Catalyst Pharmaceuticals shares are held by company insiders. Comparatively, 9.0% of Qiagen shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Do analysts rate CPRX or QGEN?

Catalyst Pharmaceuticals presently has a consensus price target of $31.14, indicating a potential upside of 46.42%. Qiagen has a consensus price target of $51.88, indicating a potential upside of 16.13%. Given Catalyst Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Catalyst Pharmaceuticals is more favorable than Qiagen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Catalyst Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	3.00
Qiagen	0 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.67

Summary

Catalyst Pharmaceuticals beats Qiagen on 15 of the 18 factors compared between the two stocks.